AFSTYLA Antihemophilic Factor (Recombinant), Single Chain

openFDA label record#

This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.

Verified complete openFDA source JSON (canonical bytes are SHA-256 checked before publication)

Brand name
AFSTYLA Antihemophilic Factor (Recombinant), Single Chain
Generic name
ANTIHEMOPHILIC FACTOR, HUMAN RECOMBINANT
Manufacturer
CSL Behring Lengnau AG
Product type
PLASMA DERIVATIVE
SPL set ID
51f19873-a63f-4229-9477-5da4ecf31cde
SPL ID
757ccd2f-85b7-440f-905f-b999e2d1dd4b
Version
13
Effective date
2023-06-23
Source export date
2026-11-13
Source partition
2
Source file
https://download.open.fda.gov/drug/label/drug-label-0002-of-0014.json.zip
Source object key
raw/openfda/drug-label/2026-11-13/3b4204ed830f35b16ab24b2123672d7d93066eb0fd8af1cf09b223d0e4568221/drug-label-0002-of-0014.json.zip
Source manifest SHA-256
8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
Import run
20261116T150851Z
Imported at
2026-11-16 15:31:45

Warnings cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Warnings sections page 1 of 1 · 1 matching rows.

warnings and cautions

5 WARNINGS AND PRECAUTIONS Hypersensitivity reactions, including anaphylaxis, are possible. Should symptoms occur, immediately discontinue AFSTYLA and administer appropriate treatment. ( 5.1 ) Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of AFSTYLA; previously untreated patients (PUPs) are at greater risk.. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform an assay that measures Factor VIII inhibitor concentration. ( 5.2 ) If the one-stage clotting assay is used, multiply the result by a conversion factor of 2 to determine the patient's Factor VIII activity level. ( 5.3 ) 5.1 Hypersensitivity Reactions Allergic-type hypersensitivity reactions, including anaphylaxis, are possible with AFSTYLA. Inform patients of the early signs of hypersensitivity reactions that may progress to anaphylaxis (including hives, generalized urticaria, tightness of the chest, wheezing, hypotension and pruritus). Immediately discontinue administration and initiate appropriate treatment if hypersensitivity reactions occur. For patients with previous hypersensitivity reactions, consider premedication with antihistamines. 5.2 Neutralizing Antibodies Formation of neutralizing antibodies (inhibitors) to Factor VIII has been reported following administration of AFSTYLA; previously untreated patients (PUPs) are at greatest risk [see Adverse Reactions (6.2) ] . Monitor patients for the development of neutralizing antibodies (inhibitors) by appropriate clinical observations and laboratory tests. If expected plasma Factor VIII activity levels are not attained, or if bleeding is not controlled after AFSTYLA administration, the presence of an inhibitor (neutralizing antibody) should be suspected [see Warnings and Precautions (5.3) ] . Contact a specialized hemophilia treatment center if a patient develops an inhibitor. 5.3 Monitoring Laboratory Tests Monitor plasma Factor VIII activity in patients receiving AFSTYLA using either the chromogenic assay or the one-stage clotting assay, which is routinely used in US clinical laboratories. The chromogenic assay result most accurately reflects the clinical hemostatic potential of AFSTYLA and is preferred. The one-stage clotting assay result underestimates the Factor VIII activity level compared to the chromogenic assay result by approximately one-half. If the one-stage clotting assay is used, multiply the result by a conversion factor of 2 to determine the patient's Factor VIII activity level. Incorrect interpretation of the Factor VIII activity obtained by the one-stage clotting assay could lead to unnecessary additional dosing, higher chronic dosing, or investigations for an inhibitor. Monitor for the development of Factor VIII inhibitors. Perform a Bethesda inhibitor assay if expected plasma Factor VIII activity levels are not attained or if bleeding is not controlled with the expected dose of AFSTYLA. Use Bethesda Units (BU) to report inhibitor levels.

Adverse reactions cross-check#

openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.

Adverse reactions sections page 1 of 1 · 2 matching rows.

adverse reactions

6 ADVERSE REACTIONS The most common adverse reactions (>0.5% of subjects) reported in clinical trials were Factor VIII inhibition in previously untreated patients (PUPs), dizziness and hypersensitivity. The most common adverse reactions reported in clinical trials (>0.5% of subjects) were Factor VIII inhibition in previously untreated patients (PUPs), dizziness and hypersensitivity. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact the CSL Behring Pharmacovigilance Department at 1-866-915-6958 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of one drug cannot be directly compared to rates in clinical trials of another drug and may not reflect the rates observed in practice. The safety, efficacy and pharmacokinetics of AFSTYLA have been evaluated in 258 previously treated patients (PTPs) and 24 previously untreated patients (PUPs) with severe hemophilia A (<1% endogenous Factor VIII activity) who received at least one dose of AFSTYLA as part of either routine prophylaxis, on-demand treatment of bleeding episodes or perioperative management in two completed clinical trials (an adult/adolescent study [≥12 to 65 years of age] and a pediatric study [<12 years of age]), and an extension study (0 to ≤65 years of age PTPs and 0 to ≤5 years old PUPs). Patients with a history of, or current FVIII inhibitors, or any first order family history of FVIII inhibitors, patients with known hypersensitivity (allergic reaction or anaphylaxis) to any FVIII product or hamster protein, and patients with evidence of thrombosis, including deep vein thrombosis, stroke, pulmonary embolism, myocardial infarction and arterial embolus within 3 months prior to Day 1 of the study were excluded from study participation. One hundred eight (38.3%) subjects were children <12 years of age (59 [20.9%] 0 to <6 years and 49 [17.4%] ≥6 to <12 years), 14 (5.0%) were adolescents (≥12 to <18 years), and 160 (56.7%) were adults (≥18 to ≤65 years). In PTPs there have been a total of 28,418 exposure days (EDs), with at least 28,492 injections of AFSTYLA administered. In the completed studies, a total of 185 subjects achieved at least 50 EDs, of whom 60 subjects achieved ≥100 EDs. In PUPs there have been a total number of 5909 EDs, with 5914 injections, 21 subjects achieved ≥50 EDs. Adverse reactions (ARs) (summarized in Table 3) were reported for 14 of 258 (5.4%) subjects in all studies. An adverse reaction of hypersensitivity resulted in the withdrawal of one subject. Among PTPs no subject developed neutralizing antibodies (inhibitors) to Factor VIII. No PTPs and PUPs developed antibodies to host cell proteins. No events of anaphylaxis or thrombosis were reported. Table 3. Adverse Reactions Reported for AFSTYLA (N=258) Adverse reactions reported in adult/adolescent and pediatric studies in previously treated patients MedDRA System Organ Class Adverse Reactions Number of Subjects n (%) Immune system disorders Hypersensitivity 4 (1.6) Nervous system disorders Dizziness 2 (0.8) Paresthesia 1 (0.4) Skin and subcutaneous tissue disorders Rash 1 (0.4) Erythema 1 (0.4) Pruritus 1 (0.4) General disorders and administration site conditions Pyrexia 1 (0.4) Injection-site pain 1 (0.4) Chills 1 (0.4) Feeling hot 1 (0.4) 6.2 Immunogenicity All subjects were monitored for inhibitory and binding antibodies to AFSTYLA, and binding antibodies to chinese hamster ovary (CHO) host cell proteins prior to the first infusion of AFSTYLA, at defined intervals during the studies and at the end of study visit. Data from a completed clinical trial in previously untreated patients (PUPs) aged ≤5 years indicate that: 12 (50%; 95% CI: [29.1%, 70.9%]) of 24 treated subjects developed an inhibitor to Factor VIII. Of 22 subjects with at least 50 EDs or who developed inhibitor at any time, 6 (27.3%) developed high titer inhibitors (≥ 5BU) and 6 (27.3%) developed low titer inhibitors (<5BU). The overall median EDs until initial inhibitor development was 10 EDs (range: 4 to 23). Of the 12 subjects who tested positive for inhibitors, 11 subjects have remained in the trial; 9 experienced successful eradication of the inhibitor. The median (range) EDs to inhibitor eradication was 37 (16 to 194). The median (range) time to inhibitor eradication was 14.3 (7.7 to 64.4) weeks. Two subjects with high titer inhibitors remain inhibitor positive: one subject was withdrawn from the immune tolerance induction (ITI) substudy after approximately 12 months, another subject completed ITI substudy after approximately 24 months. No PTPs developed neutralizing antibodies (inhibitors) to Factor VIII or antibodies against CHO host cell proteins at any time during the completed clinical studies. Four subjects in the adult/adolescent study and 10 subjects in the pediatric study were negative for non-neutralizing anti-drug antibodies (ADAs) at screening and turned positive during the clinical study. Two of the adult/adolescent subjects and three of the pediatric subjects who developed ADAs were negative at end of study visit. No adverse events were associated with the development of ADAs. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody positivity in an assay may be influenced by several factors, including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, it may be misleading to compare the incidence of antibodies to AFSTYLA with the incidence of antibodies to other products. 6.3 Postmarketing Experience The following adverse reaction has been identified during post-approval use of AFSTYLA. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood and lymphatic systems disorders: Factor VIII inhibitor development

adverse reactions table

<table width="85%"><caption>Table 3. Adverse Reactions Reported for AFSTYLA (N=258)<footnote>Adverse reactions reported in adult/adolescent and pediatric studies in previously treated patients</footnote></caption><col width="40%" align="left" valign="top"/><col width="30%" align="left" valign="top"/><col width="30%" align="center" valign="top"/><thead><tr><th align="center">MedDRA System Organ Class</th><th align="center">Adverse Reactions</th><th align="center">Number of Subjects n (%)</th></tr></thead><tbody><tr><td><content styleCode="bold">Immune system disorders</content></td><td>Hypersensitivity</td><td>4 (1.6)</td></tr><tr><td><content styleCode="bold">Nervous system disorders</content></td><td>Dizziness</td><td>2 (0.8)</td></tr><tr><td/><td>Paresthesia</td><td>1 (0.4)</td></tr><tr><td rowspan="2"><content styleCode="bold">Skin and subcutaneous tissue disorders</content></td><td>Rash</td><td>1 (0.4)</td></tr><tr><td>Erythema</td><td align="center">1 (0.4)</td></tr><tr><td/><td>Pruritus</td><td>1 (0.4)</td></tr><tr><td rowspan="2"><content styleCode="bold">General disorders and administration site conditions</content></td><td>Pyrexia</td><td>1 (0.4)</td></tr><tr><td>Injection-site pain</td><td align="center">1 (0.4)</td></tr><tr><td/><td>Chills</td><td>1 (0.4)</td></tr><tr><td/><td>Feeling hot</td><td>1 (0.4)</td></tr></tbody></table>

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.